NASDAQ$LUNG
Pulmonx Corporation · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Pulmonx reported record fourth quarter and full year 2024 financial results, with significant revenue growth and improved net loss.
Pulmonx reported record worldwide revenue of $23.8 million for Q4 2024, a 23% increase year-over-year, and $83.8 million for the full year 2024, a 22% increase. The company also achieved a gross margin of 74% for both the quarter and the full year, and reduced its net loss compared to the previous year.
- Record worldwide revenue of $23.8 million in Q4 2024, up 23% year-over-year.
- Record full year 2024 worldwide revenue of $83.8 million, up 22% year-over-year.
- Gross margin of 74% achieved for both Q4 and full year 2024.
- Net loss improved to $13.2 million in Q4 2024 and $56.4 million for full year 2024.
Headline financials
Revenue & EPS history
Pulmonx · Revenue · Quarterly
$23.8M
Forward guidance
Pulmonx expects full year 2025 revenue to be between $96 million and $98 million, representing 15% to 17% growth (16% to 18% on a constant currency basis), with an expected gross margin of approximately 74% and total operating expenses between $133 million and $135 million.
Tailwinds
- Expected revenue growth of 15% to 17% for full year 2025.
- Expected constant currency revenue growth of 16% to 18% for full year 2025.
- Anticipated gross margin of approximately 74% for full year 2025.
- Continued investments in commercial activities and clinical development.
- Confidence in driving long-term, sustainable growth in 2025 and beyond.
Headwinds
- Guidance assumes a negative impact from foreign exchange on reported revenue growth of approximately 100 basis points.
- Total operating expenses are expected to be between $133 million and $135 million.
- Approximately $22 million of non-cash stock-based compensation is included in operating expenses.
- Potential risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
- No obligation to update or review any estimate, projection, or forward-looking statement unless required by law.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-3.4%
Avg return
Earnings day
-4.1%
Avg return
5 days after
-5.3%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+32.2%
Q4 2024
Best reaction
-64.7%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.5% | -6.7% | +12.6% | |
| Q4 2025 | +0.6% | -6.1% | -28.2% | |
| Q3 2025 | -18.9% | -28.6% | +29.1% | |
| Q1 2025 | -21.9% | -28.8% | -29.6% | |
| Q4 2024 | +32.2% | +30.7% | +17.0% | |
| Q3 2024 | -7.7% | +5.2% | -4.7% | |
| Q2 2024 | -8.1% | -15.4% | +3.7% | |
| Q1 2024 | +23.3% | +21.9% | -4.7% | |
| Q4 2023 | -17.7% | -27.9% | -36.1% | |
| Q3 2023 | +6.9% | +20.7% | +34.2% | |
| Q2 2023 | -4.1% | -8.0% | -26.0% | |
| Q1 2023 | +1.1% | -0.2% | -1.5% | |
| Q4 2022 | +20.8% | +26.0% | +27.1% | |
| Q3 2022 | -64.7% | -61.1% | -52.3% | |
| Q2 2022 | +9.2% | +19.9% | +5.7% | |
| Q1 2022 | +0.6% | -23.6% | -23.9% | |
| Q4 2021 | -6.9% | -2.5% | -12.5% | |
| Q3 2021 | +7.1% | +12.6% | -23.7% | |
| Q2 2020 | -7.6% | -10.9% | -1.6% | |
| Q2 2021 | +0.1% | +6.0% | +3.3% | |
| Q1 2020 | -5.8% | -5.3% | +9.9% | |
| Q1 2021 | -8.7% | -9.6% | -10.3% | |
| Q4 2020 | -4.1% | -3.4% | -20.2% | |
| Q3 2020 | -4.9% | -3.4% | +5.6% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro